FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Inclusion Criteria: * Locally advanced or metastatic solid tumor malignancies that have relapsed or progressed after at least one line of therapy and where the following anti-PD-L1 are approved: avelumab, atezolizumab or durvalumab * Capable of giving signed informed consent * Aged ≥ 18 years old * Willingness to comply with study procedures and duration * Measurable disease per iRECIST * Contraceptive use for women and men as defined in the protocol Exclusion Criteria: * Pregnant or breast-feeding women * ECOG performance status ≥ 2 * Evidence of insufficient organ function * Clinically significant cardiovascular disease * Receipt of therapy within 2 weeks prior to Day 1 or five half-lives, whichever is shorter or any investigational therapy within 28 days prior to Day 1 * Known active central nervous system (CNS) involvement by malignancy * Non-malignant CNS disease such as stroke, epilepsy, CNS vasculitis or neurodegenerative disease or receipt of medications for these conditions * Currently receiving or likely to require immunosuppressive therapy * Known active infections with Hepatitis B, Hepatitis C or HIV * Live vaccine within 6 weeks prior to start of lympho-conditioning * Known allergy to albumin (human) or DMSO